Evidence map›Paper›PMID 39970186›Full record

ReviewAmerican journal of physiology. Cell physiology2025

Utilizing

Zhangjie Wang, Jian Liu

Abstract readReview
In one paragraph

Review in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhangjie WangGlycan Therapeutics Corp., Raleigh, North Carolina, United States.ORCID 0000-0003-4301-953X
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States.ORCID 0000-0001-8552-1400

Funding

Development of heparan sulfate-based therapeutics to treat inflammatory diseasesR44GM144019 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI WANG, ZHANGJIE · 2023 to 2025
$2.4M
Development of analytical methods for glycosaminoglycans from biological sourcesR44GM142304 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI WANG, ZHANGJIE · 2022 to 2023
$2.0M
HHS | NIH | National Institute of General Medical Sciences (NIGMS) 5R44GM142304HHS | NIH | National Institute of General Medical Sciences (NIGMS) R44GM144019NIGMS NIH HHS R44 GM142304NIGMS NIH HHS R44 GM144019
6 · The paper itself

Abstract

Heparan sulfate (HS) is a highly sulfated and structurally heterogeneous polysaccharide that plays key roles in numerous biological processes. Due to its complex structure and variable sulfation patterns, accurately characterizing and quantifying HS in biological samples poses significant analytical challenges. This review presents an advanced high-performance liquid chromatography-tandem mass spectroscopy (LC-MS/MS) methodology that utilizes isotope-labeled internal standards for the precise quantification of HS disaccharides and rare 3-

Indexed as

Carbon IsotopesHeparan SulfateTandem Mass SpectrometryAnimalsChromatography, High Pressure LiquidHumansIsotope LabelingCarbon-13Carbon IsotopesHeparan Sulfate13C-labeled internal standardsHS disaccharide/3-O-sulfated tetrasaccharideHS metabolismLC-MS/MSsulfatase

Identifiers

PMID39970186
PMCPMC12242996

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.